Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Glaukos ( (GKOS) ).
On May 29, 2025, Glaukos Corporation held its annual meeting of stockholders, where three key proposals were voted on. The election of three Class I directors, approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor for 2025 were all passed, reflecting strong shareholder support and setting the stage for continued corporate governance and financial oversight.
The most recent analyst rating on (GKOS) stock is a Buy with a $131.00 price target. To see the full list of analyst forecasts on Glaukos stock, see the GKOS Stock Forecast page.
Spark’s Take on GKOS Stock
According to Spark, TipRanks’ AI Analyst, GKOS is a Neutral.
The overall score of 55.4 reflects strong revenue growth and a solid balance sheet, but is weighed down by persistent losses and poor valuation metrics. The earnings call provided positive momentum with record sales and strong cash position, though profitability challenges remain significant.
To see Spark’s full report on GKOS stock, click here.
More about Glaukos
Glaukos Corporation operates in the medical technology industry, focusing on developing and commercializing innovative therapies for treating glaucoma, corneal disorders, and retinal diseases. The company is known for its pioneering work in micro-invasive glaucoma surgery and is committed to advancing eye care worldwide.
Average Trading Volume: 1,037,361
Technical Sentiment Signal: Hold
Current Market Cap: $5.42B
For an in-depth examination of GKOS stock, go to TipRanks’ Stock Analysis page.